

Curriculum Vitae

Personal information **Ulrich Rohr**

Work experience

Current

Organization: **SWISSMEDIC (Swiss Agency for Therapeutic Products)**

September 2017-ongoing Head of Hematology & Oncology Unit , Marketing Authorization, Switzerland

Since 8/2019-ongoing Head of Hematology & Oncology Unit 2 & Deputy Head of Division Clinical Review, Marketing Authorization

Key area of Work: International Collaborations with FDA, EMA, MHRA, Health Canada, TGA; Cooperation on FDA Project ORBIS and process implementation at Swissmedic

Marketing authorization for hematological & oncological drug dossiers in Switzerland

Representation of Clinical Review, Swissmedic to internal & external stakeholders with focus on hematology and Oncology

Previous Positions

Organization: **Roche Sequencing Solutions, Roche Diagnostics Division**

Position: Chief Medical Officer

9/2015 – 8/2017

Organization: **Medical and Scientific Affairs, Roche Diagnostics Division**

Position: Head of Medical and Scientific Affairs, VP

Dates 4/2009-9/2015

Organization: **Late Stage Drug Development, Roche Pharma Division**

Position Lead Clinical Scientist

Dates 1/2007-3/2009

Education and training

EDUCATION:

Medical:	Medical School:	Justus-Liebig University
	Location:	Gießen, Germany
	Dates attended	1990-1996
Residency:	Program:	Hematology and Oncology
(Arzt im Praktikum)	Location:	Medical Clinic V, Univ. of
Heidelberg, Germany	Dates attended	1996-1997

MEDICAL PRACTICE**EXPERIENCE:**

outpatient Clinic V, Germany	Clin. Specialization	Resident in Hematology and Oncology
	Name of clinic	Medical Clinic and
	Location	University of Heidelberg,
	Research Activities	Post-doc research assistant at the "German Cancer Research Center" in Heidelberg/ Germany in therapeutic gene transfer
	Dates	1998-1999
Germany	Clin. Specialization	Specialist and Assistant Medical Director for Hematology and Oncology
	Name of clinic	Department of Hematology, Oncology and Clinical Immunology
	Location	University of Düsseldorf,
	Qualification	Assistant professor („Privatdozent“) with postdoctoral lecture qualification in 2006
	Dates	1999-2006
Germany	Specialization	Assistant professor („Privatdozent“) and lecturer for Internal Medicine, Hematology and Oncology
	Name of clinic	Abteilung Innere Medizin I Hämatologie und Onkologie
	Location	University of Freiburg,
	Dates	2007-2010

Since 2010, ongoing: Full Professorship (APL Professor) and lecturer for hematology, oncology and internal medicine at the University of Freiburg, Germany

Additional information

Publications Publication Index 1998-2023 Ulrich-Peter Rohr, MD

1. Rohr UP, Heinzinger M, Rheinländer B, Parwaresch R, Bohle RM. Significance of differential nuclear expression of Ki-67 in adult soft tissue sarcomas. *Verh Dtsch Ges Pathol.* 1998;82:345-50
2. Schönrich G, Raftery M, Schnitzler P, Rohr UP, Goldschmidt H. Absence of a correlation between Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) and multiple myeloma. *Blood.* 1998;92:3474-5
3. Bohle RM, Heinzinger M, Rheinländer B, Brettreich S, Borkhardt A, Rohr UP. Oncogenes and oncoproteins in primary adult soft tissue sarcomas. *Verh Dtsch Ges Pathol.* 1998;82:423-27
4. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, Dietze L, Kronenwett R, Hünertürkoglu A, Haas R. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. *Bone Marrow Transplant.* 2001;28:47-9
5. Chalkiadaki A, Rohr UP, Hefter H. Early pain reduction in the treatment of spasticity after a single injection of botulinum A toxin. *Dtsch Med Wochenschr.* 2001;126:1361-4.
6. Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Aivado M, Koch J, Modlich O, Bojar H, Gattermann N, Haas R. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. *Blood.* 2002;99:2037-44.
7. Kronenwett R, Graf T, Nedbal W, Weber M, Steidl U, Rohr UP, Mohler T, Haas R. Inhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides. *Cancer Gene Ther.* 2002;9:587-96.
8. Rohr UP, Kronenwett R, Grimm D, Kleinschmidt J, Haas R. Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression. *J Virol Methods.* 2002;105:265-75.
9. Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R. Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. *J Virol Methods.* 2002;106:81-8.

10. Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl U, Fenk R, Opalka B, Pitschke G, Prisack HB, Bojar H, Haas R, Kronenwett R. Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector.
Cancer Gene Ther. 2003;10:898-906.
11. Fenk R, Ak M, Kobbe G, Steidl U, Arnold C, Korthals M, Hunerliturkoglu A, Rohr UP, Kliszewski S, Bernhardt A, Haas R, Kronenwett R. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Haematologica. 2004;89:557-566.
12. Steidl U, Bork S, Schaub S, Selbach O, Seres J, Aivado M, Schroeder T, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Bornstein SR, Haas HL, Kobbe G, Tenen DG, Haas R, Kronenwett R. Primary human CD34+ hematopoietic stem and progenitor cells express functionally active receptors of neuromediators.
Blood. 2004;104:81-8.
13. Rohr UP, Rehfeld N, Pflugfelder L, Geddert H, Muller W, Steidl U, Fenk R, Graf T, Schott M, Thiele KP, Gabbert HE, Germing U, Kronenwett R, Haas R. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer.
Int J Cancer. 2004;111:259-63.
14. Fenk R, Hoyer B, Steidl U, Kondakci M, Graef T, Heuk R, Ruf L, Strupp C, Neumann F, Rohr UP, Hildebrandt B, Haas R, Kobbe G. Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.
Leukemia. 2005;19:156-9.
15. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Graf T, Rohr UP, Bork S, Kronenwett R, Haas R, Kobbe G. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Bone Marrow Transplant. 2005;35:33-6
16. Rohr UP, Rehfeld N, Geddert H, Pflugfelder L, Bruns I, Neukirch J, Rohrbeck A, Grote HJ, Steidl U, Fenk R, Opalka B, Gabbert HE, Kronenwett R, Haas R. Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer.
Clin Cancer Res. 2005;11:180-5
17. Rohr UP, Heyd F, Neukirchen J, Wulf MA, Queitsch I, Kroener-Lux G, Steidl U, Fenk R, Haas R, Kronenwett R. Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles.
J Virol Methods. 2005; 127:40-45
18. Steidl U, Schroeder T, Steidl C, Kobbe G, Graef T, Bork S, Pechtel S, Kliszewski S, Kuendgen A, Rohr UP, Fenk R, Schroeder M, Haase D, Haas R, Kronenwett R.
Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera.
Ann N Y Acad Sci.2005; 1044:94-108.
19. Graef T, Steidl U, Nedbal W, Rohr UP, Fenk R, Haas R, Kronenwett R. Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis.

20. Grote HJ, Schmiemann V, Geddert H, Rohr UP, Kappes R, Gabbert HE, Bocking A.
Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer.
Int J Cancer. 2005; 116:720-5
21. Rehfeld N, Geddert H, Atamna A, Rohrbeck A, Garcia G, Kliszewski S, Neukirchen J, Bruns I, Steidl U, Fenk R, Gabbert HE, Kronenwett R, Haas R, Rohr UP. The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer.
J Carcinog. 2006; 5:4-9.
22. Papewalis C, Fassnacht M, Willenberg HS, Domberg J, Fenk R, Rohr UP, Schinner S, Bornstein SR, Scherbaum WA, Schott M. Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.
Clin Endocrinol 2006; 65:215-22.
23. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, Hubel K, Haas R, Kobbe G. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Transfusion 2006; 46:180-5.
24. Rehfeld N, Geddert G, Atamna A, Gabbert H, Steidl U, Fenk R, Kronenwett R, Haas R, Rohr UP. Coexpression of FHIT and c-kit is relevant for prediction of survival in patients with small cell lung cancer.
Cancer Epidermiology, Biomarkers and Prevention 2006; 11:2232-8
25. Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Roskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, von Haeseler A, Gattermann N, Haas R, Kronenwett R. Molecular signature of CD34 hematopoietic stem and progenitor cells of patients with CML in chronic phase.
Leukemia 2007 Mar;21(3):494-504.
26. Neukirchen J, Meier A, Rohrbeck A, Garcia G, Steidl U, Fenk R, Haas R, Kronenwett R, Rohr UP. Divergent effects of the proteasome inhibitor bortezomib in combination with p53 gene transfer or cytotoxic chemotherapy in non-small cell lung cancer cells
Cancer Gene Ther. 2007 14:431-9
27. Pivarcsi A, Müller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, Seeliger S, Kubitz A, Pippirs U, Meller S, Gerber PA, Liersch R, Buenemann E, Sonkoly E, Wiesner U, Hoffmann TK, Schneider L, Piekorz R, Enderlein E, Reifemberger J, Rohr UP, Haas R, Boukamp P, Haase I, Nürnberg B, Ruzicka T, Zlotnik A, Homey B. Tumor immune escape by the loss of homeostatic chemokine expression.
Proc. Nat. Acad. Sci. 2007 104:19055-60 27.
28. Rohrbeck A, Neukirchen J, Roskopf M, Pardillos GG, Geddert H, Schwalen A, Gabbert HE, von Haeseler A, Pitschke G, Schott M, Kronenwett R, Haas R, Rohr UP. Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers.
J Transl Med. 2008; 6:69.
29. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect

of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

J Cancer Res Clin Oncol. 2010;136:737-43.

30. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16:269-78.
31. Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirzén F, Lyman GH, Rohr UP. Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies. J Clin Oncol. 2011 Mar 21.
32. Rohr UP, Walk E, MD, Teichgräber V, Liesenfeld O, Batrla O, Lee JA. Emerging Trends in Oncology Testing: Enhancing the medical value of diagnostics. CLPmag. 2012; (Sep):8-13
33. Desiere F, Gutjahr TS, Rohr UP. Developing companion diagnostics for delivering personalised medicine: opportunities and challenges. Drug Discovery Today: Therapeutic Strategies 2013
34. Schäfer H, Filser L, Rohr UP, Laubender RP, Dieterle T, Maitland R, Zaugg CE. Medical Value as a new strategy to increase corporate viability: Market chances and limitations in the diagnostic industry. J Entrepren Organiz Manag 2015, 4:1
35. Schäfer H, Filser L, Rohr UP, Messina C, Laubender P, Dieterle T, Toerien E, Zaugg CE. The Diagnostic Industry in a Changing Health Care Environment. A Focus on the Value Component. Journal of Management Research Vol. 15, No. 2, April–June 2015: 91–100
36. Vyberg M, Nielsen S, Røge R, Sheppard B, Ranger-Moore J, Walk E, Gartemann J, Teichgräber V, Rohr UP. HER2-based treatment decisions in breast cancer: test accuracy and its clinical, economic and social impact. BMC Health Serv Res. 2015 Aug 29;15:352. doi: 10.1186/s12913-015-1018-6
37. Ghosh P, Tie J, Muranyi A, Singh S, Brunhoeber P, Leith K, Bowermaster R, Liao Z, Zhu Y, LaFleur B, Tran B, Desai J, Jones I, Croxford M, Jover R, Goel A, Waring P, Hu S, Teichgraber V, Rohr UP, Ridder R, Shanmugam K, Gibbs P. [Girdin \(GIV\) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer](#). Clin Cancer Res. 2016 Jul 15;22(14):3488-98. doi: 10.1158/1078-0432.CCR-15-2290.
38. Rohr UP, Binder C, Dieterle T, Giusti F, Messina CG, Toerien E, Moch H, Schäfer HH. [The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report](#). PLoS One. 2016 Mar 4;11(3):e0149856. doi: 10.1371.
39. Rohr UP, Herrmann P, Ilm K, Zhang H, Lohmann S, Reiser A, Muranyi A, Smith J, Burock S, Osterland M, Leith K, Singh S, Brunhoeber P, Bowermaster R, Tie J, Christie M, Wong HL, Waring P, Shanmugam K, Gibbs P, Stein U. Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies. accepted,

40. de Claro RA, Spillman D, Hotaki LT, Shum M, Mouawad LS, Santos GML, Robinson K, Hunt M, Healy C, Chan A, Looi YH, Rodrigues C, Rohr UP, Walther C, Pazdur. Project Orbis: Global Collaborative Review Program. R. Clin Cancer Res. 2020 Dec 15;26(24):6412-6416
41. Koch AL, Vellanki PJ, Drezner N, Li X, Mishra-Kalyani PS, Shen YL, Xia H, Li Y, Liu J, Fourie Zirkelbach J, Palazov E, Gamarian A, Choo Q, Girčys A, Rohr UP, Fesenko N, Spillman D, Pazdur R, Beaver JA, Singh HFDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review.. Clin Cancer Res. 2021 Jul 22
42. Hotaki TL, Shrestha A, Bennett M, Valdes IL, Lee SH, Wang Y, Spillman D, MacAulay T, Hunt M, Gervais J, Mafi M, Panetta V, Looi YH, Shum M, Atiek E, Meincke R, Rohr UP, Ainbinder D, Boehm-Cagan A, Luxenburg O, Cerqueira MR, Mouawad L, Thees M, Prasad K, de Claro RA. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners. Ther Innov Regul Sci 2023 Apr 18. doi: 10.1007/s43441-023-00522-4
43. Rohr UP, Iovino M, Rudofsky L, Li Qiyu, Juritz S, Gircys A, Wildner O, Bujar M, Bolte C, Dalla Torre de Sanguinetto S, Wolfer A. A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration. Clin Transl Sci. 2023 Jul 5. doi: 10.1111/cts.13567.

Projects

2006 Best Abstract at German, Austrian and Swiss Society of Hematology and Oncology: Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie und Onkologie (DGHO) at Leipzig, Germany: „Molecular profiling of tumor progression in NSCLC“, Onkologie 2006:161

2009 ASCO oral abstract and ASCO plenary highlights presentation: “Safety of bevacizumab in patients with metastases to the central nervous system” (ASCO 30.5.2009, abstract #2007, JCO 2009 Vol. 27, No15S) and ASCO highlights Plenary Lung session, 01.06.09) as oncology practice changing

2014 German Felix Burda Award for best prevention idea in colon cancer: development of MACC1
<http://www.felix-burda-award.de/preistraeger/preistraeger-2014-und-2013/index.php>

Memberships

American Society of Clinical Oncology (ASCO)
 since 2007

European Society for Clinical Oncology (ESMO)
 since 2009

Other Relevant Information